CysLT1 Receptor Inhibitors
SEE ALSO...
Items 1 to 10 of 21 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MK-571 | 115103-85-0 | sc-201340 sc-201340A | 5 mg 25 mg | $107.00 $413.00 | 8 | |
MK-571 functions as a selective antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), exhibiting unique binding characteristics that disrupt leukotriene-mediated signaling. Its structural conformation allows for effective competition with endogenous ligands, leading to altered receptor dynamics. The compound's interaction profile influences downstream signaling cascades, impacting cellular behavior and contributing to the modulation of inflammatory responses. Its kinetic properties enable a swift blockade of receptor activation, underscoring its role in receptor regulation. | ||||||
Montelukast Sodium | 151767-02-1 | sc-202231 sc-202231A sc-202231B | 10 mg 25 mg 250 mg | $50.00 $83.00 $158.00 | 5 | |
Selectively binds to CysLT1 receptor, inhibiting leukotriene activity. | ||||||
SR 2640 hydrochloride | 105350-26-3 | sc-204902 sc-204902A | 10 mg 50 mg | $290.00 $1000.00 | ||
SR 2640 hydrochloride acts as a potent antagonist of the CysLT1 receptor, characterized by its ability to selectively inhibit leukotriene binding. Its unique molecular architecture facilitates strong interactions with the receptor's active site, effectively preventing conformational changes that trigger signaling pathways. This compound exhibits rapid kinetics, allowing for immediate receptor blockade, which alters cellular responses and influences various physiological processes. Its distinct interaction dynamics contribute to the modulation of receptor activity. | ||||||
Zafirlukast | 107753-78-6 | sc-204942 sc-204942A | 10 mg 100 mg | $36.00 $171.00 | 1 | |
Acts as a selective antagonist to CysLT1 receptor, blocking leukotriene effects. | ||||||
LY 171883 | 88107-10-2 | sc-203120 | 10 mg | $72.00 | ||
LY 171883 functions as a selective antagonist of the CysLT1 receptor, distinguished by its unique binding affinity that disrupts leukotriene-mediated signaling. The compound's structural features enable it to form specific interactions with key amino acid residues within the receptor, stabilizing a non-active conformation. This selective engagement alters downstream signaling cascades, showcasing its potential to influence cellular behavior through precise molecular interactions and modulation of receptor dynamics. | ||||||
L-655,238 | 101910-24-1 | sc-221799 sc-221799A | 10 mg 50 mg | $122.00 $486.00 | ||
L-655,238 acts as a selective antagonist of the CysLT1 receptor, characterized by its ability to modulate receptor conformation through unique hydrophobic and electrostatic interactions. Its distinct molecular architecture allows for preferential binding to the receptor's active site, effectively inhibiting leukotriene-induced pathways. This compound's kinetic profile reveals a rapid onset of action, highlighting its potential to finely tune receptor activity and influence associated signaling networks. | ||||||
ONO 1078 | 103177-37-3 | sc-204148 | 50 mg | $65.00 | ||
Blocks CysLT1 receptor, reducing leukotriene-mediated effects. | ||||||
Cinalukast | 128312-51-6 | sc-203893 sc-203893A | 10 mg 50 mg | $224.00 $902.00 | ||
Cinalukast functions as a selective antagonist of the CysLT1 receptor, exhibiting a unique binding affinity that disrupts leukotriene signaling. Its molecular structure facilitates specific interactions with receptor domains, altering conformational dynamics. The compound's interaction kinetics suggest a competitive inhibition mechanism, allowing for precise modulation of downstream signaling pathways. Additionally, its solubility characteristics enhance its accessibility to target sites, influencing receptor engagement. | ||||||
Loratadine | 79794-75-5 | sc-203117 sc-203117A | 10 mg 50 mg | $107.00 $455.00 | 1 | |
Antihistamine that may indirectly affect CysLT1 receptor activity. | ||||||
FPL 55712 | 40786-08-1 | sc-203583 | 10 mg | $210.00 | ||
FPL 55712 acts as a potent antagonist of the CysLT1 receptor, characterized by its ability to stabilize the receptor in an inactive conformation. This compound exhibits a high degree of specificity, engaging in unique hydrogen bonding and hydrophobic interactions that prevent leukotriene binding. Its rapid association and dissociation rates indicate a dynamic equilibrium, allowing for fine-tuned regulation of receptor activity. The compound's lipophilicity further aids in its effective membrane penetration, optimizing receptor interaction. | ||||||